WHO will resume testing on hydroxychloroquine


The World Health Organization (WHO) will resume tests on the efficacy against hydroxychloroquine coronavirus, a malaria drug that according to preliminary assessments had been described as potentially useful for preventing coronavirus infection (without any scientific confirmation) .

WHO suspended testing on May 25 following an article published in the medical journal Lancet: The article claimed that the drug increased the mortality rate of patients with COVID-19 and the risk of an irregular heart beat. Hydroxychloroquine is also known because, in mid-May, U.S. President Donald Trump said he had started hydroxychloroquine therapy to prevent COVID-19.

The news of the resumption of the tests was given today, Wednesday, by the WHO director general, Tedros Adhanom Ghebreyesus, who explained that experts with whom he consulted do not consider it reasonable to interrupt them. The study published on Lancet it was in fact questioned by various scholars and Tuesday Lancet and the New England Journal of Medicine both expressed concern about the article and how the data was interpreted.

We started talking about the use of hydroxychloroquine in February, following a laboratory test that had shown its ability to prevent coronavirus from binding to cells, the first step to then be able to exploit them to replicate. The test had been performed in vitro, therefore not in an organism, and had some limitations in its implementation. A study done in China instead included a control group, noting some improvement in patients with mild cases of COVID-19. Again, the research involved a limited number of people.

Source link


Please enter your comment!
Please enter your name here